• Transcript covers Solventum’s Q2 FY 2026 earnings call attended by CEO Bryan Hanson, CFO Wayde McMillan, IR head Amy Wakeham.
• Management moved to separate Health Information Systems, citing limited synergies, easier carve-out, inbound interest, potential value unlock via sale or spin.
• Q2 sales were $2.2 billion; organic growth was 9.5%, including about $125 million of ERP-related advanced orders expected to mostly reverse in Q3.
• EPS was $2.55, including $0.34 from advanced orders, $0.48 from a $100 million one-time tariff refund; free cash flow was $144 million.
• Raised 2026 EPS guide to $7.1-$7.2; organic sales growth guide to 2.5%-3%, excluding a 100-basis-point SKU exit impact.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solventum Corporation published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.